ストックスクリーナーアプリを入手
15.73
0.63%
-0.10
Rallybio Corp (RLYB) 最新ニュース
Rallybio Corp (RLYB) director exercises stock options, lifts stake to 6,542 shares - Stock Titan
Rallybio Corporation (RLYB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Adar1 Capital, Daniel Schneeberger buy $2.18m Rallybio stock By Investing.com - Investing.com Nigeria
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own? - Stocktwits
Rallybio Company Profile & Introduction - Moomoo
Rallybio Corporation(NasdaqCM: RLYB) added to Russell Microcap Value Benchmark Index - marketscreener.com
Rallybio Corporation(NasdaqCM: RLYB) added to Russell Microcap Index - marketscreener.com
RLYB stock hits 2-year highs after unveiling merger with Avenzo – how much of the new company will Rallybio shareholders own? - MSN
What's Driving Rallybio's Recent Surge and Investor Interest - Kavout | AI
Rallybio Corporation Actuals & Estimates (NASDAQ:RLYB) - TradingView
Rallybio Corporation (RLYB) Shows Modest Uptick, Testing Key Resistance LevelsLate Stage Breakouts - dars.gov.et
Rallybio Corp (RLYB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rallybio Corp (RLYB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rallybio Corp (RLYB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rallybio Corp (RLYB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rallybio Corp (RLYB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rallybio Corp (RLYB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rallybio Corp (RLYB) Institutional Confidence - TradingKey
Rallybio Corp (RLYB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rallybio Corp (RLYB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RLYB Q1 2026 Earnings: Wider-Than-Expected Loss Underscores Pre-Revenue StageEarnings Call Q&A - dars.gov.et
RLBY Q1 2026 Earnings: EPS Misses Estimates as Operating Losses ContinueEarnings Preview - dars.gov.et
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
JOHNSON & JOHNSON's Rallybio Corp(RLYB) Holding History - GuruFocus
San Diego Biotech Upstart Avenzo Plots Nasdaq Splash In Rallybio Reverse Merger - Hoodline
United StatesMintz Advising On $215 Million Private Placement Concurrent With Avenzo Therapeutics’ And Rallybio’s Merger Transaction - Mondaq
Avenzo Picks Up Reverse Merger Ditched by Candid - San Diego Business Journal
ADAR1, Daniel Schneeberger disclose 17.5% stake in Rallybio (RLYB) - Stock Titan
Adar1 Capital, Daniel Schneeberger buy $2.18m Rallybio stock - Investing.com
Mintz Advising on $215 Million Private Placement Concurrent with Avenzo Therapeutics’ and Rallybio’s Merger Transaction - Mintz
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio CorporationRLYB - Business Wire
Shareholder Alert: Ademi LLP investigates whether Rallybio Corpo - GuruFocus
Halper Sadeh LLC is Investigating Whether RLYB, KALV, INM, TMHC are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders - PR Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Rallybio, Avenzo agree oncology reverse merger backed by $215 million financing - The Pharma Letter
Rallybio to Raise $215M Via Pvt Placement >RLYB - Moomoo
Rallybio: Placement Expected to Fund Ops Into Late 2028 >RLYB - Moomoo
Rallybio: Combined Co Expected to Operate As Avenzo Therapeutics >RLYB - Moomoo
RLYB: Merger leverages oncology expertise and $215M funding to advance clinical programs and milestones - TradingView
2.64%
大文字化:
|
ボリューム (24 時間):